Jilma B - Search Results

1

Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.

Cramer JP, Dubischar K, Eder S, Burchard GD, Jelinek T, Jilma B, Kollaritsch H, Reisinger E, Westritschnig K. Cramer JP, et al. Among authors: jilma b. Vaccine. 2016 Aug 31;34(38):4579-4585. doi: 10.1016/j.vaccine.2016.07.029. Epub 2016 Jul 25. Vaccine. 2016. PMID: 27460550 Clinical Trial.

2

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS. Firbas C, et al. Among authors: jilma b. Vaccine. 2006 May 15;24(20):4343-53. doi: 10.1016/j.vaccine.2006.03.009. Epub 2006 Mar 20. Vaccine. 2006. PMID: 16581161 Clinical Trial.

3

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial.

Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, Schranz S, Jong E, Klingler A, Dewasthaly S, Klade CS. Tauber E, et al. Among authors: jilma b. Lancet. 2007 Dec 1;370(9602):1847-53. doi: 10.1016/S0140-6736(07)61780-2. Lancet. 2007. PMID: 18061060 Clinical Trial.

4

Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.

Tauber E, Kollaritsch H, von Sonnenburg F, Lademann M, Jilma B, Firbas C, Jelinek T, Beckett C, Knobloch J, McBride WJ, Schuller E, Kaltenböck A, Sun W, Lyons A. Tauber E, et al. Among authors: jilma b. J Infect Dis. 2008 Aug 15;198(4):493-9. doi: 10.1086/590116. J Infect Dis. 2008. PMID: 18588481 Clinical Trial.

5

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.

Schuller E, Jilma B, Voicu V, Golor G, Kollaritsch H, Kaltenböck A, Klade C, Tauber E. Schuller E, et al. Among authors: jilma b. Vaccine. 2008 Aug 12;26(34):4382-6. doi: 10.1016/j.vaccine.2008.05.081. Epub 2008 Jun 17. Vaccine. 2008. PMID: 18599165 Clinical Trial.

6

Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51.

Schuller E, Klade CS, Heinz FX, Kollaritsch H, Rendi-Wagner P, Jilma B, Tauber E. Schuller E, et al. Among authors: jilma b. Vaccine. 2008 Nov 11;26(48):6151-6. doi: 10.1016/j.vaccine.2008.08.056. Epub 2008 Sep 17. Vaccine. 2008. PMID: 18804132 Clinical Trial.

7

Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine.

Firbas C, Boehm T, Buerger V, Schuller E, Sabarth N, Jilma B, Klade CS. Firbas C, et al. Among authors: jilma b. Vaccine. 2010 Mar 11;28(12):2397-407. doi: 10.1016/j.vaccine.2009.12.072. Epub 2010 Jan 9. Vaccine. 2010. PMID: 20060945 Clinical Trial.

8

Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up.

Dubischar-Kastner K, Kaltenboeck A, Klingler A, Jilma B, Schuller E. Dubischar-Kastner K, et al. Among authors: jilma b. Vaccine. 2010 Sep 7;28(39):6463-9. doi: 10.1016/j.vaccine.2010.07.040. Epub 2010 Jul 29. Vaccine. 2010. PMID: 20673824

9

Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51.

Eder S, Dubischar-Kastner K, Firbas C, Jelinek T, Jilma B, Kaltenboeck A, Knappik M, Kollaritsch H, Kundi M, Paulke-Korinek M, Schuller E, Klade CS. Eder S, et al. Among authors: jilma b. Vaccine. 2011 Mar 21;29(14):2607-12. doi: 10.1016/j.vaccine.2011.01.058. Epub 2011 Feb 1. Vaccine. 2011. PMID: 21288804 Clinical Trial.

10

A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.

Westritschnig K, Hochreiter R, Wallner G, Firbas C, Schwameis M, Jilma B. Westritschnig K, et al. Among authors: jilma b. Hum Vaccin Immunother. 2014;10(1):170-83. doi: 10.4161/hv.26565. Epub 2013 Sep 24. Hum Vaccin Immunother. 2014. PMID: 24064511 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

575 results

Search Page

Filters